Delivery of Adipose Derived Stem Cells for Healing Surgical Hernia Repairs

递送脂肪干细胞用于治愈疝气修复手术

• 批准号: 8484968
• 负责人: Bruce Lamb
• 金额: $ 24.37万
• 依托单位: AFFINERGY, LLC
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-10 至 2012-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8484968
• 关键词: Delivery; Adipose; Derived; Stem; Cells

DESCRIPTION (provided by applicant): Over 700,000 surgical hernia repairs are performed each year in the United States and despite recent advances, a significant rate of recurrence persists. Incisional or visceral hernia repairs account for 100,000 of these surgeries costing 1.7B annually, and have a recurrence rate of 25% for an initial repair and 44% after a second repair. The incorporation of biocompatible mesh to strengthen the abdominal fascia has largely replaced high-tension suturing techniques in surgical hernia repair. Currently, the preferred biomaterials include durable synthetic mesh, which bears all the pitfalls of a permanent foreign body; absorbable mesh which does not provide enough long-term support; or bioprosthetics, which are bioabsorbable but fail at an unacceptably high rate causing recurrent hernias. Surgeons are therefore left to choose between a foreign body and a weak repair. Our goal is to accelerate healing rates after hernia repair by using bioprosthetics containing adipose-derived stem cells (ASCs). ASCs were identified in 2001, and have been used for cell therapy in many indications including bone fractures, myocardial repair and soft tissue repair. Their prohealing function is largely mediated through paracrine factors secreted at the site of injury to promote vascularization, and tissue remodeling. The product prototype we envision will be a point-of-care ASC seeded bioprosthetic that will promote faster healing times, prevent infection, and leave a biologic repair. Our bioprosthetic is designed to prevent recurrence of incisional hernias, thereby reducing inpatient follow-up care, additional surgeries, and patient distress.

描述（由申请人提供）：美国每年进行超过 700,000 例疝气修复手术，尽管最近取得了进展，但复发率仍然很高。其中切口疝或内脏疝修补术占其中的 100,000 例，每年费用为 1.7B，首次修复的复发率为 25%，第二次修复后的复发率为 44%。在疝气修复手术中，采用生物相容性网片来强化腹部筋膜已在很大程度上取代了高压缝合技术。目前，首选的生物材料包括耐用的合成网，它具有永久性异物的所有缺陷；可吸收网不能提供足够的长期支撑；或生物假体，它们是可生物吸收的，但失败率高得令人无法接受，导致疝气复发。因此，外科医生只能在异物修复和弱修复之间做出选择。我们的目标是通过使用含有脂肪干细胞 (ASC) 的生物修复术来加快疝气修复后的愈合速度。 ASC于2001年被发现，并已用于多种适应症的细胞治疗，包括骨折、心肌修复和软组织修复。它们的促愈合功能主要是通过损伤部位分泌的旁分泌因子介导的，以促进血管形成和组织重塑。我们设想的产品原型将是一种即时 ASC 种子生物修复体，它将促进更快的愈合时间、预防感染并留下生物修复。我们的生物假体旨在预防切口疝复发，从而减少住院患者的后续护理、额外手术和患者痛苦。